Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "We want to sell Ranbaxy Laboratories. The one percent rally that comes after such big declines, it does not change the trend."
"We see the context and the markets themselves rallied in the last half an hour but they went choppy throughout the day so I would not put much importance to the rally. Ranbaxy is a short sell. A little more upside and then we sell it," he said. Also Read: EU fines Ranbaxy, others for blocking cheaper drugs
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
